NRX Share Price Performance
Recent NRX News & Updates
No updates
NurExone Biologic Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.072
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
NurExone Biologic Inc. Competitors
About NRX
- Founded
- 2020
- Employees
- n/a
- CEO
- WebsiteView website
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
Canadian Market Performance
- 7 Days: 0.2%
- 3 Months: 11.0%
- 1 Year: 18.3%
- Year to Date: 10.3%
The market has been flat in the last week, however the Industrials sector is down 3.0%. Meanwhile, the market is actually up 18% over the past year. Earnings are forecast to grow by 12% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading